BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3471 related articles for article (PubMed ID: 19302907)

  • 1. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK; Babul N; Ahdieh H
    Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
    Gould EM; Jensen MP; Victor TW; Gammaitoni AR; White RE; Galer BS
    Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH; Xiang Q; Gould EM
    Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
    Ahdieh H; Ma T; Babul N; Lee D
    J Clin Pharmacol; 2004 Jul; 44(7):767-76. PubMed ID: 15199081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study.
    Malonne H; Coffiner M; Sonet B; Sereno A; Vanderbist F
    Clin Ther; 2004 Nov; 26(11):1774-82. PubMed ID: 15639689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE
    Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M; Khan A; Kutch M; Li S
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee.
    Babul N; Noveck R; Chipman H; Roth SH; Gana T; Albert K
    J Pain Symptom Manage; 2004 Jul; 28(1):59-71. PubMed ID: 15223085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 174.